소아용 폐기능 모니터 시장 : 세계 예측(2026-2032년)

The Pediatric Lung Function Monitor Market is projected to grow by USD 1.82 billion at a CAGR of 6.24% by 2032.

Pediatric Lung Function Monitoring: Executive Overview

Pediatric lung function monitors support the assessment and longitudinal management of respiratory conditions in children and adolescents. Their value is linked to earlier recognition of deterioration, more consistent follow-up, and improved communication between families and clinicians. Adoption depends on measurement reliability, child-friendly design, clinical workflow integration, affordability, and the ability to interpret readings alongside symptoms and established diagnostic testing.

Care Pathways Are Shifting Toward Connected, Preventive Monitoring

Respiratory care is moving from episodic assessment toward ongoing monitoring across hospitals, outpatient practices, schools, and homes. This shift increases the importance of portable devices, simple operating procedures, age-appropriate interfaces, remote data sharing, and clear escalation pathways. Interoperability, data governance, reimbursement conditions, and clinician confidence remain central to translating device readings into effective care decisions.

Artificial Intelligence Strengthens Interpretation, Triage, and Personalization

Artificial intelligence can enhance pediatric lung function monitoring by identifying trends, flagging deviations from an individual baseline, supporting adherence analysis, and prioritizing cases for clinical review. Its safe use requires representative pediatric datasets, transparent validation, careful handling of growth-related changes, and safeguards against overreliance on automated outputs. AI should complement-not replace-clinical examination, validated pulmonary testing, and professional judgment.

Regional Insights: Uneven Infrastructure Shapes Adoption Priorities

North America benefits from comparatively developed pediatric respiratory services, digital health infrastructure, and remote-care pathways, while Latin America faces variation in access, reimbursement, and device distribution. Europe emphasizes clinical evidence, privacy, interoperability, and coordinated health systems. The Middle East is developing specialist capacity alongside digitally enabled care, whereas Africa requires solutions that accommodate resource constraints, workforce shortages, and connectivity variability. Asia-Pacific combines advanced markets with large, diverse care environments, making affordability, localization, and scalable training especially important.

Group Insights: Policy Alignment and Procurement Capacity Matter

ASEAN markets generally require adaptable deployment models that address differing regulatory systems, languages, and healthcare infrastructure. BRICS economies span substantial variation in manufacturing capacity, public-sector procurement, and access to specialist care. The European Union places strong emphasis on harmonized regulation, data protection, and cross-border health-system compatibility. G7 settings typically have stronger clinical research and digital infrastructure but face demanding evidence and integration requirements. GCC countries can support centralized, technology-enabled programs, while NATO members reflect diverse national procurement and clinical governance environments.

Country Insights: Local Health Systems Require Tailored Execution

Australia and Canada must address dispersed populations and remote access, while the United States combines advanced specialty care with complex reimbursement and fragmented delivery. Brazil, Mexico, India, China, Russia, and South Korea present distinct combinations of urban concentration, public-sector provision, regulatory requirements, and digital-health maturity. Japan emphasizes precision, usability, and integration within an aging yet highly developed health system. France, Germany, Italy, Spain, and the United Kingdom require alignment with national or regional procurement, evidence, privacy, and clinical workflow expectations. Across these countries, pediatric training, calibration support, multilingual materials, and equitable access are recurring execution priorities.

Priorities for Leaders: Build Clinically Trusted, Accessible Monitoring Programs

Industry leaders should prioritize validated performance across pediatric age groups, intuitive use by children and caregivers, and workflows that connect measurements with symptoms and action plans. Partnerships with pediatric respiratory specialists, health systems, schools, and patient communities can improve usability and adherence. Organizations should establish robust cybersecurity and privacy controls, transparent AI governance, interoperable data architectures, and post-deployment monitoring. Commercial and implementation strategies should also account for training, maintenance, reimbursement, local regulation, and equitable access rather than focusing solely on device functionality.

Research Methodology: Evidence-Led Assessment of the Pediatric Monitoring Landscape

The assessment should combine structured review of peer-reviewed clinical literature, regulatory and reimbursement documents, public health guidance, procurement materials, and documented technology practices. Findings should be triangulated across regions, country health systems, care settings, and stakeholder groups, including clinicians, caregivers, patients, administrators, and technology specialists. Analysis should distinguish established evidence from emerging practices, evaluate clinical utility and implementation barriers, and avoid unsupported claims about adoption, performance, or commercial outcomes.

Conclusion: Trust, Integration, and Equity Will Define Progress

Pediatric lung function monitoring can strengthen respiratory care when measurements are reliable, understandable, and connected to timely clinical action. The most durable progress will come from combining child-centered design with rigorous validation, responsible AI, interoperable systems, and practical support for caregivers and clinicians. Regional and national differences make flexible implementation essential, but the underlying objective is consistent: earlier insight, safer management, and more equitable respiratory care for children.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pediatric Lung Function Monitor Market, by Device Type

• 7.1. Introduction
• 7.2. Oscillometry Devices
  • 7.2.1. Forced Oscillation Technique
  • 7.2.2. Impulse Oscillometry
• 7.3. Peak Flow Meters
  • 7.3.1. Electronic Peak Flow Meters
  • 7.3.2. Mechanical Peak Flow Meters
• 7.4. Spirometers
  • 7.4.1. Desktop Spirometers
  • 7.4.2. Portable Spirometers

8. Pediatric Lung Function Monitor Market, by Mode

• 8.1. Introduction
• 8.2. Home Based
• 8.3. In Clinic

9. Pediatric Lung Function Monitor Market, by Application

• 9.1. Introduction
• 9.2. Diagnosis
• 9.3. Monitoring
• 9.4. Research & Clinical Trials

10. Pediatric Lung Function Monitor Market, by End User

• 10.1. Introduction
• 10.2. Clinics
• 10.3. Home Care Settings
• 10.4. Hospitals
• 10.5. Research Institutes & Labs

11. Pediatric Lung Function Monitor Market, by Region

• 11.1. Introduction
• 11.2. Asia-Pacific
• 11.3. North America
• 11.4. Latin America
• 11.5. Europe
• 11.6. Middle East
• 11.7. Africa

12. Pediatric Lung Function Monitor Market, by Group

• 12.1. Introduction
• 12.2. ASEAN
• 12.3. GCC
• 12.4. European Union
• 12.5. BRICS
• 12.6. G7
• 12.7. NATO

13. Pediatric Lung Function Monitor Market, by Country

• 13.1. Introduction
• 13.2. United States
• 13.3. Canada
• 13.4. Mexico
• 13.5. Brazil
• 13.6. United Kingdom
• 13.7. Germany
• 13.8. France
• 13.9. Russia
• 13.10. Italy
• 13.11. Spain
• 13.12. China
• 13.13. India
• 13.14. Japan
• 13.15. Australia
• 13.16. South Korea

14. Competitive Landscape

• 14.1. Market Share Analysis, 2025
• 14.2. Market Concentration Analysis, 2025
  • 14.2.1. Concentration Ratio (CR)
  • 14.2.2. Herfindahl Hirschman Index (HHI)
• 14.3. Recent Developments & Impact Analysis, 2025
• 14.4. Product Portfolio Analysis, 2025
• 14.5. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Becton, Dickinson and Company
• 15.2. COSMED Srl
• 15.3. eResearch Technology GmbH
• 15.4. Geratherm Medical AG
• 15.5. Koninklijke Philips N.V.
• 15.6. Medical International Research (MIR) Srl
• 15.7. Medikro Oy
• 15.8. MGC Diagnostics Corporation
• 15.9. Minato Medical Science Co., Ltd.
• 15.10. ndd Medizintechnik AG
• 15.11. nSpire Health, Inc.
• 15.12. Schiller AG
• 15.13. Sibel SA
• 15.14. Thorasys Thoracic Medical Systems Inc.
• 15.15. Vitalograph Ltd.
• 15.16. Vyaire Medical, Inc.

16. Key Experts